Biology
Neutrophil Extracellular Traps in Venous Thromboembolism Pathogenesis
Quick fact
Neutrophil extracellular traps were only discovered in 2004, yet they are now implicated in various thrombotic diseases, including deep vein thrombosis and pulmonary embolism.
Why this is interesting
You've likely heard that blood clots can be triggered by injury or long flights. But what if your immune system—the defense force that fights infections—could also trigger dangerous clots?
Read the full explanation
Understanding Neutrophil Extracellular Traps in Venous Thromboembolism Pathogenesis
Imagine a spider web designed to trap bacteria. Neutrophils, a type of white blood cell, release these webs, called neutrophil extracellular traps (NETs), to ensnare and kill microbes. The web is made of DNA studded with proteins like histones and enzymes. However, NETs also serve as a scaffold for clot formation. When NETs are released inside a blood vessel, they can activate platelets, promote the formation of fibrin, and inhibit natural anti-clotting mechanisms, thereby promoting the development of a venous thrombus. This explains how infections or inflammatory conditions can increase the risk of venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism.
A deeper explanation
NETs promote thrombosis through several coordinated mechanisms. The DNA and histones in NETs provide a physical and chemical surface that binds platelets and red blood cells, and they also recruit key clotting components. Histones, especially, are cytotoxic to endothelial cells, causing damage that exposes tissue factor, a potent initiator of the coagulation cascade. Furthermore, NETs are rich in tissue factor itself and other procoagulant factors, amplifying the cascade. NETs also inactivate tissue factor pathway inhibitor (TFPI) and thrombomodulin, reducing natural anticoagulation. Additionally, NETs act as a scaffold for factor XII activation, promoting the intrinsic pathway of coagulation. This prothrombotic environment, when excessive or dysregulated, can trigger clot formation in veins, directly contributing to VTE pathogenesis. This understanding highlights potential therapeutic targets such as DNases that degrade NETs or inhibitors of PAD4, the enzyme essential for NETosis.